Moderna Inc (MRNA)

2,211.00 +71.00 (+3.32%)
Closed MXN Disclaimer

Moderna Inc Company Profile

Sector
Healthcare
Employees
5600
Equity Type
ORD
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Contact Information
Address
Cambridge,02139 United States
Phone
617 714 6500
Fax
617 649 3910
Top Executives
Name
Age
Since
Title
Sandra J. Horning 73 2020 Independent Director
Noubar B. Afeyan 60 2010 Co-Founder, Independent Non Executive Chairman & Member of Technology Advisory Board
Stephane Bancel 50 2011 CEO & Director
Ron Eydelloth 0 0000 Member of Scientific Advisory Board
Rachel Green 0 0000 Member of Scientific Advisory Board
Paul L. Sagan 64 2018 Independent Non Executive Director
Ralph Weissleder 0 0000 Member of Scientific Advisory Board
Paula T. Hammond 59 0000 Member of Scientific Advisory Board
Michael Diamond 0 0000 Member of Scientific Advisory Board
Stephen A. Berenson 62 2017 Independent Non Executive Director
Melissa J. Moore 0 2016 Member of Scientific Advisory Board
Jack W. Szostak 0 2014 Chairman of Scientific Advisory Board
Richard C. Willson 0 2014 Member of Technology Advisory Board
Robert S. Langer 75 2010 Independent Non Executive Director & Member of Scientific Advisory Board
Fred E. Regnier 0 2014 Member of Technology Advisory Board
John G. Aunins 63 2014 Member of Technology Advisory Board
James R. Swartz 0 2014 Member of Technology Advisory Board
Elizabeth G. Nabel 72 2021 Independent Director
Elizabeth Edith Tallett 74 2020 Independent Director
Ulrich H. von Andrian-Werburg 0 0000 Member of Scientific Advisory Board
Francois Nader 67 2019 Independent Non Executive Director
Clear All
0Selected
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.